N6- methyladenosine (m6A) is a critical dynamic epigenetic modification regulated by m6A methyltransferases and demethylases. m6A plays crucial roles in regulating several biological processes, including RNA stability, splicing, and translation, which have recently been associated with the development of various diseases. Among others, m6A and its regulators are involved in osteoporosis, cancer, and other endocrine and metabolic disorders. For example, FTO-mediated m6A demethylation in the 3’UTR of PPARG mRNA promotes osteogenic differentiation of mesenchymal stem cells.
The exact role of m6A modifications in endocrine disorders is yet to be fully understood. In this Research Topic, we aim to highlight the recent discoveries and advances in m6A signaling pathway targeting strategies and their clinical potential in endocrine disorders. The topic of interest include, but are not limited to:
- New drugs targeting the m6A signaling pathway for endocrine disorders;
- m6A modifications as biomarkers for endocrine disorders;
- m6A modifiers in endocrine disorders;
- Differential m6A modifications in endocrine diseases;
- m6A modifiers as potential targets for endocrine disorders.
N6- methyladenosine (m6A) is a critical dynamic epigenetic modification regulated by m6A methyltransferases and demethylases. m6A plays crucial roles in regulating several biological processes, including RNA stability, splicing, and translation, which have recently been associated with the development of various diseases. Among others, m6A and its regulators are involved in osteoporosis, cancer, and other endocrine and metabolic disorders. For example, FTO-mediated m6A demethylation in the 3’UTR of PPARG mRNA promotes osteogenic differentiation of mesenchymal stem cells.
The exact role of m6A modifications in endocrine disorders is yet to be fully understood. In this Research Topic, we aim to highlight the recent discoveries and advances in m6A signaling pathway targeting strategies and their clinical potential in endocrine disorders. The topic of interest include, but are not limited to:
- New drugs targeting the m6A signaling pathway for endocrine disorders;
- m6A modifications as biomarkers for endocrine disorders;
- m6A modifiers in endocrine disorders;
- Differential m6A modifications in endocrine diseases;
- m6A modifiers as potential targets for endocrine disorders.